Rapidly increasing severe acute respiratory syndrome coronavirus 2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 …
MR Farcet, M Karbiener, J Schwaiger… - The Journal of …, 2022 - academic.oup.com
MR Farcet, M Karbiener, J Schwaiger, R Ilk, TR Kreil
The Journal of Infectious Diseases, 2022•academic.oup.comAbstract Immunoglobulin lots (N= 176) released since March 2020 were tested for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, with first
positive results for September 2020 lots (mean, 1.7 IU/mL; 46% of lots positive). From there,
values steadily increased, in correlation with the cumulative coronavirus disease 2019
(COVID-19) incidence, to reach a mean of 31.2 IU/mL and 93% of lots positive by January
2021. Extrapolating the correlation, immunoglobulins could reach an anti–SARS-CoV-2 …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, with first
positive results for September 2020 lots (mean, 1.7 IU/mL; 46% of lots positive). From there,
values steadily increased, in correlation with the cumulative coronavirus disease 2019
(COVID-19) incidence, to reach a mean of 31.2 IU/mL and 93% of lots positive by January
2021. Extrapolating the correlation, immunoglobulins could reach an anti–SARS-CoV-2 …
Abstract
Immunoglobulin lots (N = 176) released since March 2020 were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, with first positive results for September 2020 lots (mean, 1.7 IU/mL; 46% of lots positive). From there, values steadily increased, in correlation with the cumulative coronavirus disease 2019 (COVID-19) incidence, to reach a mean of 31.2 IU/mL and 93% of lots positive by January 2021. Extrapolating the correlation, immunoglobulins could reach an anti–SARS-CoV-2 potency of approximately 345 IU/mL by July 2021. At that stage, prophylactic immunoglobulin treatment for primary/secondary immunodeficiency could contain similar doses of anti–SARS-CoV-2 as convalescent plasma that is used for treatment of COVID-19.
Oxford University Press